Evidence in focus

Poster summary: Boese K, et al. EORS (2019)*

JOURNEY® II XR® demonstrates significantly improved patient-reported outcomes at 12 months, compared to pre-total knee arthroplasty (TKA)

Plus points

- Significant improvements in all patient reported outcomes at 6 weeks post-TKA (p<0.05)
- Significant improvements in all patient reported outcomes at one year (p<0.05)

Overview

- Prospective, multicentre study investigating clinical and patient-reported outcomes of JOURNEY II XR
  - 156 patients (TKAs, 165; mean age, 63.6 years)
  - Twelve-month data available for 59 TKAs

Results

- Compared to pre-TKA, JOURNEY II XR patients demonstrated:
  - Significant improvements in Knee Injury and Osteoarthritis Outcome Scores (KOOS; Figure) and EQ5D were observed at 6 weeks, 3-months, 6-months and 12-months post-TKA (p<0.05)
  - Significant improvements were observed at 3 months vs 6 weeks and 6 months vs 3 months post-TKA for KOOS and EQ-5D scores (p<0.05)
  - Significant improvements were also observed at 12 months vs 6 months for KOOS Quality of Life and Sports and Recreational Activities scores (p<0.05)
- Two revisions post-TKA
  - One peri-prosthetic fracture at 73 days post-TKA
  - One patella loosening at 554 days post-TKA

Conclusions

Compared to pre-TKA, JOURNEY II XR results in early, clinically significant post-TKA improvements in both functional and quality of life outcomes. JOURNEY II XR demonstrates a low short-term revision risk.

Citation

*Boese K, MacDonald J, Huang W, et al. Early clinical and patient-reported results of a bi-cruciate retaining total knee implant: six-month results of a prospective multicentre study of 149 primary TKAs. Poster presented at: European Orthopaedic Research Society (EORS); October 2-4, 2019; ORS 2019; Maastricht, the Netherlands.